B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages

Experimental Cell Research

Volumn 313, Issue 2, 2007, Pages 331-340

  Hodawadekar, Suchita ^a   Yu, Duonan ^a   Cozma, Diana ^a   Freedman, Bruce ^a   Sunyer, Oriol ^a   Atchison, Michael L ^a   Thomas Tikhonenko, Andrei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B cell; Hematopoietic stem cell; Macrophage; Pax5

Indexed keywords

CD11B ANTIGEN; CD79A ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; CYTOKINE; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 7 RECEPTOR; LATEX; PROTEIN; PROTEIN EBF; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BLIMP; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DOWN REGULATION; EPIGENETICS; FEEDBACK SYSTEM; GENE SILENCING; HEMATOPOIETIC CELL; IN VITRO STUDY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OSTEOCLAST; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

MURINAE; MUS;

EID: 33845972579     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.10.015     Document Type: Article

References (46)

1. Roessler S., and Grosschedl R. Role of transcription factors in commitment and differentiation of early B lymphoid cells. Semin. Immunol. 18 (2006) 12-19
2. Glimcher L.H., and Singh H. Transcription factors in lymphocyte development-T and B cells get together. Cell 96 (1999) 13-23
3. Cantor A.B., and Orkin S.H. Hematopoietic development: a balancing act. Curr. Opin. Genet. Dev. 11 (2001) 513-519
4. Querfurth E., Schuster M., Kulessa H., Crispino J.D., Doderlein G., Orkin S.H., Graf T., and Nerlov C. Antagonism between C/EBPbeta and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors. Genes Dev. 14 (2000) 2515-2525
5. Nutt S.L., Heavey B., Rolink A.G., and Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401 (1999) 556-562
6. Singh H., Medina K.L., and Pongubala J.M. Contingent gene regulatory networks and B cell fate specification. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4949-4953
7. Hu M., Krause D., Greaves M., Sharkis S., Dexter M., Heyworth C., and Enver T. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev. 11 (1997) 774-785
8. Montecino-Rodriguez E., Leathers H., and Dorshkind K. Bipotential B-macrophage progenitors are present in adult bone marrow. Nat. Immun. 2 (2001) 83-88
9. Rekhtman N., Radparvar F., Evans T., and Skoultchi A.I. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev. 13 (1999) 1398-1411
10. Scott E.W., Simon M.C., Anastasi J., and Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265 (1994) 1573-1577
11. McKercher S.R., Torbett B.E., Anderson K.L., Henkel G.W., Vestal D.J., Baribault H., Klemsz M., Feeney A.J., Wu G.E., Paige C.J., and Maki R.A. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 15 (1996) 5647-5658
12. Zhang P., Behre G., Pan J., Iwama A., Wara-Aswapati N., Radomska H.S., Auron P.E., Tenen D.G., and Sun Z. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8705-8710
13. Zhang P., Zhang X., Iwama A., Yu C., Smith K.A., Mueller B.U., Narravula S., Torbett B.E., Orkin S.H., and Tenen D.G. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 96 (2000) 2641-2648
14. Dahl R., Walsh J.C., Lancki D., Laslo P., Iyer S.R., Singh H., and Simon M.C. Regulation of macrophage and neutrophil cell fates by the PU.1: C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat. Immunol. 4 (2003) 1029-1036
15. Xie H., Ye M., Feng R., and Graf T. Stepwise reprogramming of B cells into macrophages. Cell 117 (2004) 663-676
16. Paige C.J., Kincade P.W., and Ralph P. Murine B cell leukemia line with inducible surface immunoglobulin expression. J. Immunol. 121 (1978) 641-647
17. Principato M., Cleveland J.L., Rapp U.R., Holmes K.L., Pierce J.H., Morse H.C., and Klinken S.P. Transformation of murine bone-marrow cells with combined v-Raf-v-Myc oncogenes yields clonally related mature B-cells and macrophages. Mol. Cell. Biol. 10 (1990) 3562-3568
18. Davidson W.F., Pierce J.H., and Holmes K.L. Evidence for a developmental relationship between CD5+ B-lineage cells and macrophages. Annals N.Y. Acad. Sci. 651 (1992) 112-129
19. Holmes K.L., Pierce J.H., Davidson W.F., and Morse III H.C. Murine hematopoietic cells with pre-B or pre-B/myeloid characteristics are generated by in vitro transformation with retroviruses containing fes, ras, abl, and src oncogenes. J. Exp. Med. 164 (1986) 443-457
20. Martin M., Strasser A., Baumgarth N., Cicuttini F.M., Welch K., Salvaris E., and Boyd A.W. A novel cellular model (SPGM 1) of switching between the pre-B cell and myelomonocytic lineages. J. Immunol. 150 (1993) 4395-4406
21. DeKoter R.P., and Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288 (2000) 1439-1441
22. Nutt S.L., Metcalf D., D'Amico A., Polli M., and Wu L. Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J. Exp. Med. 201 (2005) 221-231
23. Maitra S., and Atchison M. BSAP can repress enhancer activity by targeting PU.1 function. Mol. Cell. Biol. 20 (2000) 1911-1922
24. Chiang M.Y., and Monroe J.G. BSAP/Pax5A expression blocks survival and expansion of early myeloid cells implicating its involvement in maintaining commitment to the B-lymphocyte lineage. Blood 94 (1999) 3621-3632
25. Fitzsimmons D., Hodsdon W., Wheat W., Maira S.M., Wasylyk B., and Hagman J. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev. 10 (1996) 2198-2211
26. Nutt S.L., Morrison A.M., Dorfler P., Rolink A., and Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 17 (1998) 2319-2333
27. Kozmik Z., Wang S., Dorfler P., Adams B., and Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol. Cell. Biol. 12 (1992) 2662-2672
28. Delogu A., Schebesta A., Sun Q., Aschenbrenner K., Perlot T., and Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 24 (2006) 269-281
29. Nera K.P., Kohonen P., Narvi E., Peippo A., Mustonen L., Terho P., Koskela K., Buerstedde J.M., and Lassila O. Loss of Pax5 promotes plasma cell differentiation. Immunity 24 (2006) 283-293
30. Fuxa M., Skok J., Souabni A., Salvagiotto G., Roldan E., and Busslinger M. Pax5 induces V-to-DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene. Genes Dev. 18 (2004) 411-422
31. Hesslein D.G., Pflugh D.L., Chowdhury D., Bothwell A.L., Sen R., and Schatz D.G. Pax5 is required for recombination of transcribed, acetylated, 5′ IgH V gene segments. Genes Dev. 17 (2003) 37-42
32. Nutt S.L., Thevenin C., and Busslinger M. Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology 198 (1997) 227-235
33. Hsu L.Y., Liang H.E., Johnson K., Kang C., and Schlissel M.S. Pax5 activates immunoglobulin heavy chain V to DJ rearrangement in transgenic thymocytes. J. Exp. Med. 199 (2004) 825-830
34. Johnson K., Pflugh D.L., Yu D., Hesslein D.G., Lin K.I., Bothwell A.L., Thomas-Tikhonenko A., Schatz D.G., and Calame K. B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. Nat. Immunol. 5 (2004) 853-861
35. Mikkola I., Heavey B., Horcher M., and Busslinger M. Reversion of B cell commitment upon loss of Pax5 expression. Science 297 (2002) 110-113
36. Yu D., and Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21 (2002) 1922-1927
37. Yu D., Allman D., Goldscmidt M., Atchison M., Monroe J.G., and Thomas-Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101 (2003) 1950-1955
38. Wells A.D., Gudmundsdottir H., and Turka L.A. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J. Clin. Invest. 100 (1997) 3173-3183
39. Li J., Peters R., Lapatra S., Vazzana M., and Sunyer J.O. Anaphylatoxin-like molecules generated during complement activation induce a dramatic enhancement of particle uptake in rainbow trout phagocytes. Dev. Comp. Immunol. 28 (2004) 1005-1021
40. Greaves M., Janossy G., and Doenhoff M. Selective triggering of human T and B lymphocytes in vitro by polyclonal mitogens. J. Exp. Med. 140 (1974) 1-18
41. Lin K.I., Angelin-Duclos C., Kuo T.C., and Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol. Cell. Biol. 22 (2002) 4771-4780
42. Busslinger M. Transcriptional control of early B cell development. Annu. Rev. Immunol. 22 (2004) 55-79
43. Kee B.L., and Murre C. Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helix-loop-helix transcription factor E12. J. Exp. Med. 188 (1998) 699-713
44. Hodawadekar S., Wei F., Yu D., Thomas-Tikhonenko A., and Atchison M. Epigenetic histone modifications do not control Igk locus contraction and intranuclear localization in cells with dual B cell-macrophage potential. J. Immunol. 177 (2006) 6165-6171
45. Borrello M.A., and Phipps R.P. The B/macrophage cell: an elusive link between CD5(+) B lymphocytes and macrophages. Immunol. Today 17 (1996) 471-475
46. Feldman A.L., Minniti C., Santi M., Downing J.R., Raffeld M., and Jaffe E.S. Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol. 5 (2004) 248-250